Lyell Immunopharma
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Lyell Immunopharma's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 100% to $130,000. Profit margin reached -180486%. Total operating expenses were $247,138,000.
Profit Margin
| 2019 | 657K | -121.25M | -18456.01% |
|---|---|---|---|
| 2020 | 7.75M | -198.53M | -2559.73% |
| 2021 | 10.65M | -285.50M | -2680.76% |
| 2022 | 84.68M | -4.75M | -5.61% |
| 2023 | 130K | -234.63M | -180486.15% |
LYEL Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 130K | 84.68M | 10.65M | 7.75M | 657K |
Cost of revenue | 0 | 16.46M | 14.53M | 7.47M | 0 |
Gross profit | 130K | 68.21M | -3.88M | 281K | 657K |
Operating exp. | |||||
Research and development | 182.94M | 159.18M | 138.69M | 182.24M | 63.59M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 247.13M | 276.49M | 225.42M | 219.69M | 102.74M |
Operating income | -247.00M | -183.11M | -214.77M | -211.93M | -102.08M |
Other income (expenses), net | 12.37M | -178.36M | -35.44M | 7.46M | -27.28M |
Income before tax | -234.63M | -183.11M | -250.21M | -204.47M | -129.37M |
Income tax expense | 0 | -178.36M | 35.28M | -5.93M | -8.12M |
Net income | -234.63M | -4.75M | -285.50M | -198.53M | -121.25M |
Earnings per share | |||||
Basic EPS | -0.93 | -0.01 | -1.18 | -0.81 | -0.49 |
Diluted EPS | -0.93 | -0.01 | -1.18 | -0.81 | -0.49 |
| Data source | Data source |